<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03951194</url>
  </required_header>
  <id_info>
    <org_study_id>PRP- Perimenopause</org_study_id>
    <nct_id>NCT03951194</nct_id>
  </id_info>
  <brief_title>Ovarian Autologous Platelet-Rich Plasma (PRP) Treatment in Perimenopause.</brief_title>
  <official_title>Evaluation of Ovarian Functional Reactivation Following Injection of Autologous Platelet-rich Plasma in Perimenopausal Women.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Genesis Athens Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National and Kapodistrian University of Athens</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Genesis Athens Clinic</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Autologous ovarian Platelet Rich Plasma (PRP) treatment may enable restoration of the
      menstrual cycle in perimenopausal women, and subsequently enable the possibility of pregnancy
      employing their own oocytes.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The specific prospective clinical investigation, attempts to answer whether autologous
      Platelet Rich Plasma (PRP) injected into the ovaries can lead to regeneration and
      reactivation of the ovarian tissue in perimenopausal women.

      PRP is blood plasma prepared from fresh whole blood that has been enriched with platelets. It
      is collected from peripheral veins and contains several growth factors such as vascular
      endothelial growth factor (VEGF), epidermal growth factor (EGF), platelet derived growth
      factor (PDGF), transforming growth factor (TGF) and other cytokines all of which stimulate
      tissue proliferation and growth. Since many years, PRP has been used in several medical
      conditions in Orthopedics, Dermatology, Ophthalmology for wound healing. Its efficacy in
      ovarian rejuvenation and reactivation and endometrial regeneration has not been fully
      elucidated.

      The aim of this study is to evaluate the effectiveness of ovarian PRP injection, in order to
      reactivate ovarian function.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 13, 2019</start_date>
  <completion_date type="Anticipated">January 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">January 30, 2021</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Restoration of menstrual cycle regularity</measure>
    <time_frame>6 months</time_frame>
    <description>Regular Menstruation</description>
  </primary_outcome>
  <primary_outcome>
    <measure>FSH</measure>
    <time_frame>3 months</time_frame>
    <description>Serum levels of FSH recorded monthly</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>AMH</measure>
    <time_frame>3 months</time_frame>
    <description>Serum levels of AMH recorded monthly</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>LH</measure>
    <time_frame>3 months</time_frame>
    <description>Serum levels of LH recorded monthly</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Oestradiol</measure>
    <time_frame>3 months</time_frame>
    <description>Serum levels of E2 recorded monthly</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progesteron</measure>
    <time_frame>3 months</time_frame>
    <description>Serum levels of PRG recorded monthly</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Primordial and antral follicular count (AFC)</measure>
    <time_frame>3 months</time_frame>
    <description>Folliculogenesis reactivation TVUS monitoring of the primordial and antral follicular count (AFC)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Infertility, Female</condition>
  <condition>Perimenopausal Disorder</condition>
  <condition>Menstrual Cycle Abnormal</condition>
  <arm_group>
    <arm_group_label>Group PRP patients</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Group of patients receiving PRP treatment into the ovaries.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control Group - placebo patients</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Group of patients receiving placebo - Platelet Free Plasma (PFP) treatment into the ovaries.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Autologous Platelet rich Plasma</intervention_name>
    <description>Autologous PRP will be injected into the ovaries.</description>
    <arm_group_label>Group PRP patients</arm_group_label>
    <other_name>PRP</other_name>
    <other_name>Platelet rich Plasma</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo injected into the ovaries.</description>
    <arm_group_label>Control Group - placebo patients</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Cycle Irregularities:

          -  More than 7-day difference between two consecutive menstrual cycles OR

          -  amenorrhea of at least 60 days and continued elevation of FSH.

        Exclusion Criteria:

          -  No menstrual cycles in the last 12 months

          -  Current diagnosis of cancer

          -  Ovarian inaccessibility

          -  Current or previous premature ovarian failure

          -  Endocrinologic disorders (Thyroid Dysfunction, Diabetes mellitus, Metabolic syndrome),

          -  BMI&gt;30 kg/m2

          -  Systematic autoimmune disorders
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Agni Pantou, MD</last_name>
    <role>Study Director</role>
    <affiliation>Obstetrician Gynecologist</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Mara Simopoulou, PhD</last_name>
    <phone>+306979234100</phone>
    <email>marasimopoulou@hotmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Agni Pantou, MD, PhD Candidate</last_name>
    <email>agni.pantou@genesisathens.gr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Genesis AC</name>
      <address>
        <city>Athens</city>
        <zip>15232</zip>
        <country>Greece</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Agni Pantou, MD, PhD Candidate</last_name>
      <email>agni.pantou@genesisathens.gr</email>
    </contact>
    <contact_backup>
      <last_name>Konstantinos Pantos, MD,PhD</last_name>
    </contact_backup>
  </location>
  <location_countries>
    <country>Greece</country>
  </location_countries>
  <verification_date>July 2019</verification_date>
  <study_first_submitted>October 25, 2017</study_first_submitted>
  <study_first_submitted_qc>May 14, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">May 15, 2019</study_first_posted>
  <last_update_submitted>July 22, 2019</last_update_submitted>
  <last_update_submitted_qc>July 22, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">July 24, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infertility</mesh_term>
    <mesh_term>Infertility, Female</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

